Cargando…
Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation
BACKGROUND: Previous studies have revealed the risk factors for femoral pseudoaneurysms (FPA). Most data on FPA are based on coronary and peripheral interventions, with limited studies focusing on atrial fibrillation (AF) ablation. However, patient backgrounds, anticoagulation regimens, and vascular...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692832/ https://www.ncbi.nlm.nih.gov/pubmed/38045461 http://dx.doi.org/10.1002/joa3.12950 |
_version_ | 1785153028204003328 |
---|---|
author | Koyama, Takafumi Tobita, Kazuki Kawaguchi, Tatsuto Uchida, Shuhei Koyama, Eiji Kodera, Nobuhisa Tamaki, Yusuke Otomaru, Yuri Miyashita, Hirokazu Yamashita, Takayoshi Mizuno, Shingo Murakami, Masato Saito, Shigeru |
author_facet | Koyama, Takafumi Tobita, Kazuki Kawaguchi, Tatsuto Uchida, Shuhei Koyama, Eiji Kodera, Nobuhisa Tamaki, Yusuke Otomaru, Yuri Miyashita, Hirokazu Yamashita, Takayoshi Mizuno, Shingo Murakami, Masato Saito, Shigeru |
author_sort | Koyama, Takafumi |
collection | PubMed |
description | BACKGROUND: Previous studies have revealed the risk factors for femoral pseudoaneurysms (FPA). Most data on FPA are based on coronary and peripheral interventions, with limited studies focusing on atrial fibrillation (AF) ablation. However, patient backgrounds, anticoagulation regimens, and vascular access methods differ. In addition, a standard for managing FPA after AF ablation remains elusive due to the difficult nature of achieving thrombosis in pseudoaneurysms. METHODS: This single‐center, retrospective, observational study included 2805 consecutive patients who underwent AF ablation between January 2016 and December 2021. All patients underwent femoral artery and vein punctures. Puncture sites were checked 1 day post‐procedure. RESULTS: A total of 23 FPA patients were identified during the study period. Multivariate logistic regression analysis showed that hypertension (odds ratio 4.66, 95% confidence interval: 1.38–15.71; p = .0032) and warfarin use (odds ratio 3.83, 95% confidence interval: 1.40–10.45; p = .021) were significantly associated with the occurrence of FPA. The compression success rate was low (22%). There were nine and six patients in the endovascular treatment (EVT) and ultrasound‐guided thrombin injection (UGTI) groups, respectively. The success rates were 100% and 84% in the EVT and UGTI groups, respectively. The length of hospital stay after FPA treatment was 2.1 days in the EVT group and 1.3 days in the thrombin group. CONCLUSION: We must be careful about post‐procedural FPA, especially for hypertension and warfarin‐using patients. Treatment of pseudoaneurysms with anticoagulants is unlikely to achieve hemostasis, and an early switch to invasive treatments, such as EVT, should be considered. |
format | Online Article Text |
id | pubmed-10692832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106928322023-12-03 Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation Koyama, Takafumi Tobita, Kazuki Kawaguchi, Tatsuto Uchida, Shuhei Koyama, Eiji Kodera, Nobuhisa Tamaki, Yusuke Otomaru, Yuri Miyashita, Hirokazu Yamashita, Takayoshi Mizuno, Shingo Murakami, Masato Saito, Shigeru J Arrhythm Original Articles BACKGROUND: Previous studies have revealed the risk factors for femoral pseudoaneurysms (FPA). Most data on FPA are based on coronary and peripheral interventions, with limited studies focusing on atrial fibrillation (AF) ablation. However, patient backgrounds, anticoagulation regimens, and vascular access methods differ. In addition, a standard for managing FPA after AF ablation remains elusive due to the difficult nature of achieving thrombosis in pseudoaneurysms. METHODS: This single‐center, retrospective, observational study included 2805 consecutive patients who underwent AF ablation between January 2016 and December 2021. All patients underwent femoral artery and vein punctures. Puncture sites were checked 1 day post‐procedure. RESULTS: A total of 23 FPA patients were identified during the study period. Multivariate logistic regression analysis showed that hypertension (odds ratio 4.66, 95% confidence interval: 1.38–15.71; p = .0032) and warfarin use (odds ratio 3.83, 95% confidence interval: 1.40–10.45; p = .021) were significantly associated with the occurrence of FPA. The compression success rate was low (22%). There were nine and six patients in the endovascular treatment (EVT) and ultrasound‐guided thrombin injection (UGTI) groups, respectively. The success rates were 100% and 84% in the EVT and UGTI groups, respectively. The length of hospital stay after FPA treatment was 2.1 days in the EVT group and 1.3 days in the thrombin group. CONCLUSION: We must be careful about post‐procedural FPA, especially for hypertension and warfarin‐using patients. Treatment of pseudoaneurysms with anticoagulants is unlikely to achieve hemostasis, and an early switch to invasive treatments, such as EVT, should be considered. John Wiley and Sons Inc. 2023-11-08 /pmc/articles/PMC10692832/ /pubmed/38045461 http://dx.doi.org/10.1002/joa3.12950 Text en © 2023 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Koyama, Takafumi Tobita, Kazuki Kawaguchi, Tatsuto Uchida, Shuhei Koyama, Eiji Kodera, Nobuhisa Tamaki, Yusuke Otomaru, Yuri Miyashita, Hirokazu Yamashita, Takayoshi Mizuno, Shingo Murakami, Masato Saito, Shigeru Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation |
title | Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation |
title_full | Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation |
title_fullStr | Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation |
title_full_unstemmed | Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation |
title_short | Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation |
title_sort | incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692832/ https://www.ncbi.nlm.nih.gov/pubmed/38045461 http://dx.doi.org/10.1002/joa3.12950 |
work_keys_str_mv | AT koyamatakafumi incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT tobitakazuki incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT kawaguchitatsuto incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT uchidashuhei incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT koyamaeiji incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT koderanobuhisa incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT tamakiyusuke incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT otomaruyuri incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT miyashitahirokazu incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT yamashitatakayoshi incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT mizunoshingo incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT murakamimasato incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation AT saitoshigeru incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation |